Molecular docking of an antianxiety drug molecule "3-[2-(1H-Benzimidazol-2-ylsulfan-yl) eth-yl]-1,3-oxazolidin-2-one"
by Abdellatif Bouayyadi; Aissam El Aliani; Yassine Kasmi; Ahmed Moussaif; Abdelhalim Mesfioui; El Mokhtar Essassi; Mohammed El Mzibri
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 15, No. 1, 2022

Abstract: "3-[2- (1H-Benzimidazol-2-ylsulfan-yl) eth-yl]-1,3-oxazolidin2-one" (OXB1), was synthesised, characterised and evaluated, in silico, its binding capacity to the active site of gamma-aminobutyric acid (GABA) located in the GABA type A receptor (GABAAR). The results obtained showed a similar affinity to the 3 main isoforms of the GABAAR subtypes: α2β2γ2, α3β2γ2 and α5β2γ2 with respectively 7.3, 7.0 and 7.2. Molecular dynamic explorations showed a high stability of the complex (OXB1-GABAAR). Moreover, the evaluation of the ADMET profile of OXB1 clearly showed that this chemical exhibits good pharmacokinetic and pharmacodynamic properties and is able to cross the blood brain barrier to reach the potential targets in the brain, suggesting that this molecule could be an effective and potential anxiolytic agent that could be used for in vivo explorations to strengthen the therapeutic arsenal against anxiety with more efficacy and less side effects.

Online publication date: Mon, 08-Aug-2022

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?


Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com